Verisante Technology Inc. | Cash Flow

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
Net Income before Extraordinaries
4,896.10
3,233.40
2,389.60
1,641.60
Depreciation, Depletion & Amortization
1,059.40
1,129.70
1,098.00
924.40
Other Funds
768.80
13.30
83.60
148.30
Funds from Operations
3,067.90
2,090.40
1,375.20
568.90
Changes in Working Capital
360.90
701.90
654.30
230.40
Net Operating Cash Flow
3,428.80
1,388.50
720.90
338.40
Capital Expenditures
1,113.40
193.00
71.60
5.30
Purchase/Sale of Investments
1,021.40
-
-
-
Net Investing Cash Flow
92.00
193.00
71.60
5.30
Issuance/Reduction of Debt, Net
-
-
152.00
265.10
Net Financing Cash Flow
3,355.40
1,465.70
452.90
355.10
Net Change in Cash
165.30
115.80
339.60
11.40
Free Cash Flow
3,478.20
1,388.50
720.90
339.60
Change in Capital Stock
3,355.40
1,465.70
300.80
90.00

About Verisante Technology

View Profile
Address
2639 Viking Way
Richmond British Columbia V6V 3B7
Canada
Employees -
Website http://www.verisante.com
Updated 07/08/2019
Verisante Technology, Inc. a medical device company, which is engaged in development, regulatory, production and commercialization of skin cancer detection systems. Its products include Verisante Aura and Verisante Core. The Verisante Aura is a multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer.